



Aerie Pharmaceuticals
 Investor Relations Department
 135 US Highway 206, Suite 15
 Bedminster, NJ 07921
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: AERI

Last Trade:	54.15
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	1.70 (+3.241%)
Day Range	51.65 - 54.40
52-Week Range	16.61 - 59.50
Volume	557,540


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Rhopressa™ (netarsudi... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

- Jun 1, 2017*
[Aerie Pharmaceuticals to Present at Two Investor Conferences in June](#)
- May 26, 2017*
[Aerie Pharmaceuticals Raises \\$125 Million in ATM Sales and Upsized Follow-On Offering](#) [\(more\)](#)
- May 25, 2017*
[Aerie Pharmaceuticals Announces Public Offering of Common Stock](#)
- May 24, 2017*
[Aerie Pharmaceuticals Reports Positive Roclatan™ \(netarsudil/latanoprost ophthalmic solution\) 0.02%/0.005% Phase 3 Topline Efficacy Results](#)
- May 16, 2017*
[Aerie Pharmaceuticals Announces New Hires](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*
[Quarterly Report \(10-Q\)](#)